Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573164
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Allergic Rhinitis WithWithout Asthma Pre- and Post-Qipian Analysis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Clinical Indexes and Efficacy of Qi-pian in Patients With Allergic Rhinitis With or Without Asthma
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Allergic rhinitis and asthma are common respiratory diseases Qipian is a Chinese medicine made from three types of bacteria used to treat these conditions This study will retrospectively analyze the effects of adding Qipian to the regular treatment for patients with allergic rhinitis with or without asthma Patients meeting the Allergic Rhinitis and its Impact on AsthmaARIA and Global Initiative for AsthmaGINA diagnostic criteria were divided into two groups one receiving standard drug treatment and the other receiving standard treatment plus Qipian The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian leads to better outcomes than the standard treatment aloneThis study aims to determine how Qipian benefits patients with rhinitis and asthma and its effect on related serum indicators helping to explore its role in allergic respiratory diseases
Detailed Description:
Allergic rhinitis and asthma are common chronic respiratory diseases with rising prevalence each year Bacterial lysates BLs are a potential treatment option that has been used for over 100 years Qipian is a Chinese medication containing extracts from three types of bacteria used to treat chronic respiratory diseases It effectively alleviates symptoms and improves the immune system This study will retrospectively analyze the clinical efficacy of adding Qipian to the conventional drug treatment in patients with allergic rhinitis with or without asthma Patients diagnosed with rhinitis and asthma according to ARIA and GINA guidelines were included in the study They will be divided into two groups based on their treatment regimen a conventional drug treatment group and a conventional drug plus Qipian treatment group Clinical symptoms and relevant serum markers were collected to assess changes before and after treatment and to determine whether the addition of Qipian results in more significant improvements compared to the conventional drug treatment group This will help determine the benefits of Qipian for patients with rhinitis with or without asthma in terms of clinical symptoms and serum indicators and further explore its role in allergic respiratory diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None